National Center for Biodefense and Infectious Disease (NCBID)

Some academic

Director: Charles Bailey, PhD

Key Interests

Infectious Disease | Vaccine Development | Proteomics Genetics | Host-Pathogen Interactions | Vector Ecology | Diagnostics | Pathology | Therapeutics | Nanotechnology


Research Focus

The National Center for Biodefense and Infectious Diseases (NCBID) focuses on host- pathogen interactions in the lab applying proteomics and nanotechnology to diagnostic, therapeutic, and vaccine development. Researchers work in Mason’s Biomedical Research Laboratory, which is one of 13 regional biocontainment labs funded by NIAID/NIH. The facility is capable of housing multiple species and has a variety of established animal models with an emphasis on aerosolized exposures. Additionally, the NCBID is interested in vector- host-pathogen interactions in the field, especially during inter-epidemic periods. The team is working with collaborators in Costa Rica to facilitate field studies of vector ecology in native tropical regions, including mosquitoes that transmit Zika virus in the upper canopy of forests.

NCBID welcomes strategic alliances and collaborative relationships with defense contractors, biotechnology and pharmaceutical partners, federal government agencies, and private researchers to protect citizens nationally and internationally from potential biological threats.

NCBID has the expertise, facilities and equipment that allow researchers to ask and answer vital questions about disease.

■ Capability to perform animal studies in multiple species, from mice up to nonhuman primates

■ Aerobiology studies with nose-only, whole-body, and head-only delivery capabilities

■ Virological assays to quantify loads, including standard plaque assays, 96-well plate assays, absolute q-RT-PCR assays, and focus forming assays

■ Bacterial assays to identify biochemical activity or 16S rRNA, compound library and combinational library screening, minimal inhibitor concentration assays, minimal bactericidal concentration assays, time-kill kinetic assays, resistance development/mutant selection and microbial quantitation through q-PCR

Facilities & Equipment 

■ BSL2 and BSL3 laboratories

■ Aerobiology suite with class III hoodline and aerosol exposure cabinets 

■ IVIS Lumina II in vivo imaging

■ Necropsy suite

■ Arcturus laser capture microdissection instrument

Select Publications 

■ L. Lundberg et al., Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses. Antiviral Res. 157, 57-67 (2018).

■ B. Meltzer et al., Tat controls transcriptional persistence of unintegrated HIV genome in primary human macrophages. Virology 518, 241-252 (2018).

■ E. M. C. Chung et al., Komodo dragon-inspired synthetic peptide DRGN-1 promotes wound-healing of a mixed- biofilm infected wound. Biofilms and Microbiomes 3 (2017).